We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Karuna Therapeutics Inc | NASDAQ:KRTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 329.83 | 301.63 | 329.99 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on February 23, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KARUNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 27-0605902 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) | |
99 High Street, Floor 26 Boston, Massachusetts |
02110 | |
(Address of Principal Executive Offices) | (Zip Code) |
Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan
Karuna Therapeutics, Inc. 2019 Employee Stock Purchase Plan
(Full Title of the Plans)
William Meury
President and Chief Executive Officer
Karuna Therapeutics, Inc.
99 High Street, Floor 26
Boston, Massachusetts 02110
(857) 449-2244
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Mitchell S. Bloom, Esq. Siavosh Salimi, Esq. Goodwin Procter LLP The New York Times Building 620 Eighth Avenue New York, NY 10018 (212) 813-8800 |
Mia Kelley Vice President, Legal Affairs Karuna Therapeutics, Inc. 99 High Street, Floor 26 Boston, Massachusetts 02110 (857) 449-2244 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 relating to the 2019 Stock Option and Incentive Plan and the 2019 Employee Stock Purchase Plan of Karuna Therapeutics, Inc. (the Registrant) registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (SEC File No. 333-232521, SEC File No. 333-237360, SEC File No. 333-253501 and SEC File No. 333-262946) of the Registrant are effective. Accordingly, the information contained in the Registrants Registration Statements on Form S-8 (SEC File No. 333-232521, SEC File No. 333-237360, SEC File No. 333-253501 and SEC File No. 333-262946) filed with the Securities and Exchange Commission on July 2, 2019 is hereby incorporated by reference pursuant to General Instruction E, except for Item 8. Exhibits.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
See the Exhibit Index for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
* | Filed herewith. |
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts, on February 23, 2023.
KARUNA THERAPEUTICS, INC. | ||
By: | /s/ William Meury | |
William Meury President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Karuna Therapeutics, Inc. (the Company), hereby severally constitute and appoint William Meury and Troy Ignelzi, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments (including post-effective amendments) to this Registration Statement, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in such capacities to enable the Company to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature |
Title(s) |
Date | ||
/s/ William Meury William Meury |
President, Chief Executive Officer and Director (Principal Executive Officer) |
February 23, 2023 | ||
/s/ Troy Ignelzi Troy Ignelzi |
Chief Financial Officer (Principal Financial and Accounting Officer) |
February 23, 2023 | ||
/s/ Christopher J. Coughlin Christopher J. Coughlin |
Director | February 23, 2023 | ||
/s/ James I. Healy, M.D. James I. Healy, M.D. |
Director | February 23, 2023 | ||
/s/ Jeffrey M. Jonas, M.D. Jeffrey M. Jonas, M.D. |
Director | February 23, 2023 | ||
/s/ Laurie J. Olson Laurie J. Olson |
Director | February 23, 2023 | ||
/s/ Atul Pande, M.D. Atul Pande, M.D. |
Director | February 23, 2023 | ||
/s/ Steven Paul, M.D. |
Chief Scientific Officer, President of Research and Development, and Director | February 23, 2023 | ||
Steven Paul, M.D. | ||||
/s/ Denice M. Torres Denice M. Torres |
Director | February 23, 2023 | ||
/s/ David E. Wheadon, M.D. David E. Wheadon, M.D. |
Director | February 23, 2023 |
1 Year Karuna Therapeutics Chart |
1 Month Karuna Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions